# OnCo record pasritamig (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pasritamig/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pasritamig" ;
  schema:name "Pasritamig"@en ;
  schema:description "Pasritamig is Johnson & Johnson's bispecific T-cell engager that binds KLK2 on prostate cancer cells and CD3 on T cells, with a deliberately low-affinity CD3 arm. In phase 1 about 40% of patients had a PSA50 response with far less cytokine release syndrome than other engagers, and a phase 3 trial began in 2025."@en ;
  schema:url <https://onco.cc/drugs/pasritamig/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=JNJ-78278343> ;
  onco:status "phase-3" ;
  onco:modality "Bispecific T-cell engager (KLK2×CD3)" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/klk2/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:terms <https://onco.cc/terms/crs/> ;
  onco:trials <https://onco.cc/trials/nct07225946/> .